XML 85 R75.htm IDEA: XBRL DOCUMENT
v3.23.1

FAIR VALUE MEASUREMENTS - Narrative (Details) |  |  |  |  |  |  | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 06, 2023 shares | Apr. 07, 2022 USD ($) shares | Feb. 28, 2022 USD ($) $ / shares shares | Dec. 30, 2021 USD ($) shares | Jul. 23, 2021 USD ($) $ / shares shares | Jun. 24, 2021 USD ($) $ / shares shares | Mar. 31, 2023 USD ($) $ / shares shares | Mar. 31, 2022 USD ($) | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 16, 2022 USD ($) | Mar. 26, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Derivative liability, converted amount |  |  |  |  |  |  | $ 6,650,000 | $ 156,000 |  |  |
Balance of investments measured at fair value |  |  |  |  |  |  | $ 0 |  | $ 24,000 |  |
Common stock, shares outstanding (in shares) | shares |  |  |  |  |  |  | 103,035,152 |  | 91,442,018 |  |
Equity securities, FV-NI, gain (loss) |  |  |  |  |  |  | $ 0 | 407,393 |  |  |
Change in fair value Tonogold note receivable |  |  |  |  |  |  | $ 0 | 605,000 |  |  |
Closing stock price (in usd per share) | $ / shares |  |  | $ 1.46 |  |  |  | $ 0.34 |  | $ 0.28 |  |
Change in fair value of derivative instruments |  |  |  |  |  |  | $ 698,595 | $ 3,065,000 |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Common stock, shares outstanding (in shares) | shares | 102,707,603 |  |  |  |  |  |  |  |  |  |
Shares returned | shares | 327,549 |  |  |  |  |  |  |  |  |  |
Ionic Ventures Unsecured Convertible Promissory Note |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Threshold percentage of stock price trigger |  |  |  |  |  |  | 90.00% |  | 90.00% |  |
Ionic Ventures Unsecured Convertible Promissory Note | Measurement Input, Cap Rate |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Equity securities, measurement input (as percent) | $ / shares |  |  |  |  |  |  | 0.50 |  | 0.50 |  |
Ionic Ventures Unsecured Convertible Promissory Note | Discount rate |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Measurement input, percent |  |  |  |  |  |  |  | 35.00% | 35.00% |  |
Ionic Ventures Unsecured Convertible Promissory Note | Risk fee rate |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Measurement input, percent |  |  |  |  |  |  |  | 4.56% | 4.40% |  |
Ionic Ventures Unsecured Convertible Promissory Note | Volatility rate |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Measurement input, percent |  |  |  |  |  |  |  | 85.00% | 60.00% |  |
Ionic Ventures Unsecured Convertible Promissory Note | Subsequent Event | Secured Debt |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares returned | shares | 327,549 |  |  |  |  |  |  |  |  |  |
Quantum Generative Materials LLC |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Stock committed as investment in affiliates, subsidiaries and joint ventures |  |  |  |  |  |  | $ 1,200,000 |  | $ 2,450,000 |  |
LP Biosciences LLC |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Stock committed as investment in affiliates, subsidiaries and joint ventures |  |  |  |  | $ 4,173,000 |  |  |  |  |  |
LP Biosciences LLC | Restricted Stock | Variable Interest Entity, Not Primary Beneficiary |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares issued in connection with investment and financing commitments (in shares) | shares |  |  | 3,500,000 |  | 3,500,000 |  |  |  |  |  |
LP Biosciences LLC | Fair Value, Measurements, Recurring |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Derivative asset |  |  | $ 5,110,000 |  | $ 6,642,000 |  |  |  |  |  |
Chief Executive Officer and Officers |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of shares issued in transaction (in shares) | shares |  |  |  | 3,500,000 |  |  |  |  |  |  |
Receivable on sale of equity securities |  |  |  | $ 7,258,162 |  |  |  |  |  |  |
Tonogold Resources, Inc. |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Common stock, shares outstanding (in shares) | shares |  |  |  |  |  |  |  |  | 606,061 |  |
Tonogold Resources, Inc. | Common Stock |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Common stock, shares outstanding (in shares) | shares |  |  |  |  |  |  | 606,061 |  |  |  |
Equity securities, FV-NI, gain (loss) |  |  |  |  |  |  |  |  | $ 30,303 |  |
Gain (loss) on change in fair value |  |  |  |  |  |  | $ 0 | $ 415,205 |  |  |
Tonogold |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  | 100.00% |  |  |
Notes receivable current, before fair value adjustments |  |  |  |  |  |  |  | $ 6,650,000 |  |  | $ 6,650,000
Ionic convertible debenture derivative |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Change in fair value of derivative instruments |  |  |  |  |  |  | 210,000 | 1,330,000 |  |  |
Ionic convertible debenture derivative | Fair Value, Measurements, Recurring |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Ionic convertible debenture derivative |  |  |  |  |  |  | 5,468,162 |  | 6,053,162 |  |
Ionic convertible debenture derivative | Chief Executive Officer and Officers | Ionic convertible debenture derivative |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Stock committed as investment in affiliates, subsidiaries and joint ventures |  |  |  |  |  |  | 375,000 |  | 225,000 |  |
Ionic convertible debenture derivative | Common Stock |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Common stock, number of shares purchased (in shares) | shares |  |  |  | 3,129,081 |  |  |  |  |  |  |
Quantum Generative Materials LLC |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Closing stock price (in usd per share) | $ / shares |  |  |  |  |  | $ 3.51 |  |  |  |  |
Change in fair value of derivative instruments |  |  |  |  |  |  | 158,595 | 1,140,000 |  |  |
Quantum Generative Materials LLC | Fair Value, Measurements, Recurring |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Derivative asset |  |  |  |  |  | $ 530,000 |  |  |  |  |
Quantum Generative Materials LLC | Quantum Generative Materials LLC | Affiliated Entity |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Stock committed as investment in affiliates, subsidiaries and joint ventures |  |  |  |  |  | $ 10,000,000 |  |  |  |  |
Quantum Generative Materials LLC | Quantum Generative Materials LLC | Restricted Stock | Affiliated Entity |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock (in shares) | shares |  |  |  |  |  | 3,000,000 |  |  |  |  |
Haywood derivative |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Gain (loss) on change in fair value |  |  |  |  |  |  | 90,000 |  | 0 |  |
Derivative asset |  | $ 245,000 |  |  |  |  |  |  |  |  |
Haywood derivative | Fair Value, Measurements, Recurring |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Ionic convertible debenture derivative |  |  |  |  |  |  | 1,190,000 |  | 1,480,000 |  |
Haywood derivative | Haywood derivative | Affiliated Entity |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Stock committed as investment in affiliates, subsidiaries and joint ventures |  | $ 2,100,000 |  |  |  |  | 200,000 |  | 150,000 |  |
Issuance of common stock (in shares) | shares |  | 1,500,000 |  |  |  |  |  |  |  |  |
Deposits |  | $ 50,000 |  |  |  |  |  |  |  |  |
LP Biosciences LLC |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Closing stock price (in usd per share) | $ / shares |  |  |  |  | $ 3.09 |  |  |  |  |  |
Derivative asset |  |  | 937,000 |  |  |  |  |  |  |  |
Written off to other expense |  |  | $ 937,000 |  |  |  |  |  |  |  |
LP Biosciences LLC | Mana Corporation |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Change in fair value of derivative instruments |  |  |  |  |  |  | 595,000 |  |  |  |
Ionic Ventures, LLC |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) in derivative liabilities |  |  |  |  |  |  | 240,000 | $ 0 |  |  |
Ionic convertible debenture derivative |  |  |  |  |  |  | $ 24,000 |  | $ 420,000 | $ 420,000 |

X
- Definition Common Stock, Number of Shares Purchased + References No definition available. + Details
Name: | lode_CommonStockNumberOfSharesPurchased
Namespace Prefix: | lode_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Derivative Liability, Converted Amount + References No definition available. + Details
Name: | lode_DerivativeLiabilityConvertedAmount
Namespace Prefix: | lode_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase (Decrease) in Value of Tonogold Note Receivable Recognized in Income + References No definition available. + Details
Name: | lode_IncreaseDecreaseInValueOfTonogoldNoteReceivableRecognizedInIncome
Namespace Prefix: | lode_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Investment in Variable Interest Entity, Equity Interest Issued or Issuable, Number of Shares + References No definition available. + Details
Name: | lode_InvestmentInVariableInterestEntityEquityInterestIssuedOrIssuableNumberOfShares
Namespace Prefix: | lode_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Measurement Input, Percent + References No definition available. + Details
Name: | lode_MeasurementInputPercent
Namespace Prefix: | lode_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Notes Receivable Current, Before Fair Value Adjustments + References No definition available. + Details
Name: | lode_NotesReceivableCurrentBeforeFairValueAdjustments
Namespace Prefix: | lode_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Sale of Stock, Consideration Receivable on Transaction + References No definition available. + Details
Name: | lode_SaleOfStockConsiderationReceivableOnTransaction
Namespace Prefix: | lode_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Shares Returned + References No definition available. + Details
Name: | lode_SharesReturned
Namespace Prefix: | lode_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock Committed as Investment in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures + References No definition available. + Details
Name: | lode_StockCommittedAsInvestmentInAndAdvanceToAffiliatesSubsidiariesAssociatesAndJointVentures
Namespace Prefix: | lode_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Written Off To Other Expense + References No definition available. + Details
Name: | lode_WrittenOffToOtherExpense
Namespace Prefix: | lode_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion. + References No definition available. + Details
Name: | us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of deposit liabilities held by the entity, including, but not limited to, foreign and domestic, interest and noninterest bearing, demand deposits, saving deposits, negotiable orders of withdrawal (NOW) and time deposits. + References No definition available. + Details
Name: | us-gaap_DepositsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 + Details
Name: | us-gaap_DerivativeAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b)(1) -URI https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959 + Details
Name: | us-gaap_DerivativeGainLossOnDerivativeNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313 + Details
Name: | us-gaap_DerivativeLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_EquitySecuritiesFvNiMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 + Details
Name: | us-gaap_IncreaseDecreaseInDerivativeLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685 + Details
Name: | us-gaap_VariableInterestEntityOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=lode_IonicVenturesUnsecuredConvertiblePromissoryNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCapRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lode_QuantumGenerativeMaterialsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lode_LPBiosciencesLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=lode_ChiefExecutiveOfficerAndDirectorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lode_TonogoldResourcesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lode_TonogoldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lode_LINICOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lode_LINICOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lode_QuantumGenerativeMaterialsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lode_HaywoodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lode_HaywoodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lode_LPBiosciencesLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lode_ManaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lode_IonicVenturesLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |